-- 今週の停戦合意期限を前に、米国とイランの間で緊張が高まったことを受け、月曜日の原油価格は上昇した。 WTI原油は4.7%上昇し1バレル86.43ドル、ブレント原油は4.6%上昇し94.52ドルとなった。 イランがホルムズ海峡の開放を宣言したことで、原油価格は金曜日に急落した。これは米国が強く求めていたことだった。しかし、イランは土曜日に同海峡の支配権を取り戻した。両国は火曜日に期限を迎える2週間の停戦協定を互いに違反したと非難し合っている。 ドナルド・トランプ大統領は、米海軍が日曜日に海上封鎖を突破しようとしたイラン船籍の船舶を拿捕したと、自身のソーシャルメディア「Truth Social」に投稿した。 「中東情勢の展開により、原油価格は再び激しく変動している。緊張緩和の兆しが見え始めたかと思えば、すぐに緊張が再燃している」と、INGの商品戦略責任者ウォーレン・パターソン氏は月曜日のメモで述べた。 米国はパキスタンとの和平協議第2ラウンドに向けて交渉団を派遣しているが、イランは協議への参加を表明していない。 中東紛争により、世界で最も重要な原油輸送の要衝であるホルムズ海峡を通る輸送が混乱したため、エネルギー価格は急騰している。 「米国がイラン船籍の船舶を拿捕したことで、予定されている和平協議の行方には疑問が生じるだろう」とパターソン氏は述べた。
Related Articles
Oneview Healthcare Reports Decline in Q1 Cash Receipts From Customers; Shares Up 3%
Oneview Healthcare (ASX:ONE) reported cash receipts from customers of about 3.3 million euros for the first quarter, compared with 4.2 million euros a year earlier, according to a Monday filing with the Australian bourse.The company noted that the year-ago figure includes two large customer receipts totaling more than 2 million euros, which were due to be received during the fourth quarter of 2024 but were received in early 2025.Oneview Healthcare ended March with a cash balance of AU$17.1 million, up from AU$8.1 million at the close of 2025, per the filing.The company's shares gained 3% in recent Monday trade.
Paradigm to Advance Participants Through Day 112 Follow-Up Period in Phase Three Knee Osteoarthritis Trial, Shares Reach One-Year Low
Paradigm Biopharmaceuticals (ASX:PAR) is set to progress participants through the day 112 follow-up period for the phase three trial evaluating injectable pentosan polysulfate sodium for the treatment of pain associated with knee osteoarthritis in the June quarter, which is required for inclusion in the interim analysis dataset, according to a Monday Australian bourse filing.The independent statistical analysis results for the data set are expected around August. Timing remains subject to the scheduling and review processes of independent third parties, and there is a reasonable likelihood that final interim outcomes may extend into September, it cautioned.The interim analysis is expected to provide the first phase three evaluation of efficacy and safety for injectable pentosan polysulfate sodium in knee osteoarthritis. Primary endpoint top-line results are expected in the March 2027 quarter.Its shares fell 14% in recent trading on Monday, reaching their lowest point in over a year.
Sanan Optoelectronics Q1 Profit Down 68%, Revenue Slides 33%
Sanan Optoelectronics (SHA:600703) posted first-quarter attributable net profit of 67.5 million yuan, down 68% from 211.9 million yuan the previous year.Earnings per share declined to 0.01 yuan from 0.04 yuan, according to a weekend filing with the Shanghai bourse.Operating revenue declined 33% year over year to 2.91 billion yuan from 4.31 billion yuan.Shares of the software company declined 2% in recent trade.